# Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

> **NCT00440011** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 266 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** bimatoprost 0.03% eye drops
- **DRUG:** travoprost 0.004% eye drops

## Key facts

- **NCT ID:** NCT00440011
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 266 (ACTUAL)
- **Last updated:** 2019-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440011, "Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%". Retrieved via MORVS 2026-10-26 from https://api.morvs.ai/clinical/NCT00440011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*